Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing

Hormozgan University of Medical Sciences

Status: Completed

Conditions: Wheezing; Bronchiolitis; Cough

Treatments: Drug: Montelukast

Study type: Interventional

Funder types: Other

Identifiers

NCT01370187

Montelukast for bronchiolitis

Details and patient eligibility

About

The aim of the current study is to evaluate the effect of Montelukast in treatment of acute bronchiolitis and postbronchiolitis viral induced wheezing of infants 3 to 12 months of age in Bandar Abbas Children' hospital.

Full description

All the patients will be evaluated at the baseline, during hospitalization (daily) and at 2 months and 6 months after starting the intervention.

Enrollment: 146 patients

Sex: All

Ages: 3 to 12 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• infant in 3-12 months of age with first episode of wheezing or bronchiolitis
• written informed consent by parents

Exclusion criteria

• Previous wheezing episode or confirmed asthma or bronchiolitis
• recent bronchodilator use
• immune deficient
• immunosuppressive drug use
• croup or pneumonia diagnosis
• loss of follow up

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

146 participants in 2 patient groups

Control

No Intervention group

Description:

Control group

Montelukast

Experimental group

Description:

4mg Montelukast daily for 2 months

Treatment:

Drug: Montelukast